全球先天性蛋白 C 缺乏症治疗市场 – 行业趋势及 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球先天性蛋白 C 缺乏症治疗市场 – 行业趋势及 2030 年预测

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Congenital Protein C Deficiency Treatment Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 450.00 Million
Diagram Market Size (Forecast Year)
USD 773.18 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Baxter
  • Abbott
  • Trinity Biotech plc
  • Siemens Healthcare GmbH
  • BD

全球先天性蛋白 C 缺乏症治疗市场,按类型(I 型缺乏症和 II 型缺乏症)、治疗(疗法、手术和其他)、给药途径(口服、肠胃外、其他)、最终用户(医院、家庭护理、专科诊所、其他)、分销渠道(医院药房、网上药房、零售药房)划分 - 行业趋势和预测到 2030 年。

先天性蛋白 C 缺乏症治疗市场

先天性蛋白 C 缺乏症治疗市场分析及规模

先天性蛋白 C 缺乏症治疗市场预计将在预测期内出现显著增长。患有较轻度蛋白 C 缺乏症的人可能直到成年才出现症状(无症状)。其他人可能一直无症状。患有蛋白 C 缺乏症的人患上华法林诱发的皮肤坏死的风险更高。在普通人群中,较轻度蛋白 C 缺乏症的发病率约为 1/200-500。

Data Bridge Market Research 分析了 2023-2030 年预测期内先天性蛋白 C 缺乏症治疗市场的增长率。在上述预测期内,先天性蛋白 C 缺乏症治疗市场的预期复合年增长率趋于 7% 左右。2022 年市场价值为 4.5 亿美元,到 2030 年将增长至 7.7318 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外,Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

先天性蛋白 C 缺乏症治疗市场范围和细分

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021(可定制为 2015 - 2020)

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

类型(I 型缺乏症和 II 型缺乏症)、治疗(疗法、手术和其他)、给药途径(口服、肠胃外、其他)、最终用户(医院、家庭护理、专科诊所、其他)、分销渠道(医院药房、网上药房、零售药房)

覆盖国家

北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区

涵盖的市场参与者

Baxter (U.S.), Abbott (U.S.), Trinity Biotech plc (Ireland), Siemens Healthcare GmbH (U.S.), BD (U.S.), Sienco, Inc (U.S.), Cigna (U.S.), Shire Pharmaceuticals Limited (U.S.)

Market Opportunities

  • Rising Demand of Technologically Advanced Treatments
  • Increasing Demand for Retail Pharmacies

Market Definition

Protein C deficiency is a rare type of genetic condition that is characterized by protein C deficiency, which is a naturally occurring anticoagulant. There is a mild process in which the person affected is at risk of developing blood clots, particularly a type of blood clot called deep vein thrombosis. This clot generally forms in the legs. This is a severe form present at birth (congenital) and can cause widespread small clots in the body and life-threatening complications in infancy.  

Global Congenital Protein C Deficiency Treatment Market Dynamics

Drivers

  • Rising Demand of Drugs

The increasing demand of drugs is boosting the growth of the market. Mild congenital protein C deficiency can be cured without medication by adopting the therapies. But in case of severe congenital protein C deficiency, it is treated with drugs such as Ceprotin that help rid excess fluid from the body in the form of urine. This boosts the market growth.

  • Increasing Demand of genetic Testing

There are varied diagnostic tests that are helping in increasing the market growth. Healthcare professionals will run blood tests that will determine the activity of protein C in the blood. Besides this, molecular genetic testing can be performed as it can confirm a diagnosis of protein C deficiency, but generally is not crucial. Molecular genetic testing can detect alterations (mutations) in the PROC gene known to cause this disorder.

Opportunities

  • Rising Demand of Technologically Advanced Treatments

Diverse new techniques allow a broad range of therapies and surgeries. Alternatively, the rise in technologically advanced treatment methods, such as anticoagulant therapy, fresh frozen plasma, and genetic counselling, are expected to drive the market's growth. This factor boosts the opportunity of the congenital protein C deficiency treatment market.  

  • Increasing Demand for Retail Pharmacies

The increase in the number of drugs for congenital protein C deficiency delivered through retail pharmacies and the rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily available.

 Restraints/Challenges

  • Lack of Awareness

As it is a rare disease, thus lack of patient awareness about the disease and its associated treatments can hamper the growth of the market.  

  • High Cost

The huge expenditure associated with these agents hamper the market growth. High cost associated with diagnostic procedures and treatment methods that are hampering the market growth.

本先天性蛋白 C 缺乏症治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响,分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关先天性蛋白 C 缺乏症治疗市场的更多信息,请联系 Data Bridge Market Research 获取分析师简报,我们的团队将帮助您做出明智的市场决策,实现市场增长。

全球先天性蛋白 C 缺乏症治疗市场范围

先天性蛋白 C 缺乏症治疗市场根据类型、治疗、给药途径、分销渠道和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

类型

  • I 型缺陷
  • II 型缺陷

治疗

  • 疗法
  • 手术
  • 其他的

给药途径

  • 口服
  • 肠外
  • 其他的

最终用户

  • 医院
  • 家庭护理
  • 专科诊所
  • 其他的

分销渠道

  • 医院药房
  • 网上药店
  • 零售药店

先天性蛋白 C 缺乏症治疗市场区域分析/见解

对先天性蛋白 C 缺乏症治疗市场进行了分析,并按类型、治疗、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。

先天性蛋白质 C 缺乏症治疗市场报告涉及的主要国家 有北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于医疗保健基础设施的增长、政府支出的增加、患者认知度的提高以及患有蛋白质 C 和 S 缺乏症的患者数量的增加,在整个预测期内,亚太地区的先天性蛋白质 C 缺乏症治疗市场一直呈现积极增长。 

由于拥有主要的产品制造商、高额的研发和医疗保健支出以及熟练的专业人员,北美占据了市场主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外,在提供国家数据预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。    

竞争格局和全球先天性蛋白 C 缺乏症治疗市场份额分析

先天性蛋白 C 缺乏症治疗市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对先天性蛋白 C 缺乏症治疗市场的关注有关。

先天性蛋白 C 缺乏症治疗市场的主要参与者包括:

  • 百特(美国)
  • 雅培(美国)
  • Trinity Biotech plc(爱尔兰)
  • 西门子医疗有限公司(美国)
  • BD(美国)
  • Sienco, Inc(美国)
  • Cigna (美国)
  • 夏尔制药有限公司(美国)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on , By Type (Type I Deficiency and Type II Deficiency), Treatment (Therapies, Surgeries and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030. .
The Global Congenital Protein C Deficiency Treatment Market size was valued at USD 450.00 USD Million in 2022.
The Global Congenital Protein C Deficiency Treatment Market is projected to grow at a CAGR of 7% during the forecast period of 2023 to 2030.
The major players operating in the market include Baxter, Abbott, Trinity Biotech plc, Siemens Healthcare GmbH, BD, Sienco , Cigna, Shire Pharmaceuticals Limited.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.